You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anomaly of the Homologous Recombination (HR) pathway

Showing 1 - 25 of 4,482
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Homologous Recombination Repair Pathway Gene Mutation Spectrum

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jun 4, 2023

    Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

    Not yet recruiting
    • Melanoma
    • Fluzoparib Camrelizumab Temozolomide
    • (no location specified)
    Aug 9, 2023

    HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

    Completed
    • Epithelial Ovarian Cancer
    • +6 more
    • Evaluation of homologous recombination deficiency score
    • Beijing, Beijing, China
      Lei Li
    Mar 26, 2022

    Metastatic Melanoma Trial in San Francisco (Niraparib)

    Recruiting
    • Metastatic Melanoma
    • San Francisco, California
      California Pacific Medical Center Research Institute
    Oct 15, 2021

    Metastatic Melanoma Trial in San Francisco (Olaparib, Pembrolizumab)

    Recruiting
    • Metastatic Melanoma
    • San Francisco, California
      California Pacific Medical Center Research Institute
    Apr 30, 2021

    Castration-resistant Prostate Cancer, Metastasis Trial in France (Carboplatin)

    Terminated
    • Castration-resistant Prostate Cancer
    • Metastasis
    • Caen, France
    • +3 more
    Apr 28, 2021

    Esophageal Cancer, Gastric Cancer, Adenocarcinoma Trial in United States (Niraparib)

    Recruiting
    • Esophageal Cancer
    • +2 more
    • Tampa, Florida
    • +3 more
    Jan 18, 2023

    Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

    Active, not recruiting
    • Advanced Breast Cancer
    • +2 more
    • Talazoparib Tosylate
    • Stanford, California
      Stanford University Hospitals and Clinics
    Nov 16, 2022

    Triple Negative Breast Cancer Trial in Dallas (Drug 1: LY3023414; Drug 2: Prexasertib)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • Drug 1: LY3023414; Drug 2: Prexasertib
    • Dallas, Texas
      Baylor University Medical Center
    Jul 18, 2022

    Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8 Trial in Columbus

    Not yet recruiting
    • Locally Advanced Leiomyosarcoma
    • +6 more
    • Niraparib Tosylate Monohydrate
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Jul 25, 2022

    Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

    Terminated
    • Breast Cancer
    • Breast Cancer Metastatic
    • Niraparib 100 MG
    • Aromatase Inhibitors
    • A Coruña, Spain
    • +9 more
    Jan 17, 2023

    Ovarian Cancer Trial in Changsha (Doxorubicin Hydrochloride Liposome Injection+carboplatin, paclitaxel +carboplatin)

    Recruiting
    • Ovarian Cancer
    • Doxorubicin Hydrochloride Liposome Injection+carboplatin
    • paclitaxel +carboplatin
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Apr 7, 2021

    Breast Cancer Trial in Dallas (Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis)

    Recruiting
    • Breast Cancer
    • Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
    • Dallas, Texas
      Baylor University Medical Center, Baylor Charles A Sammons Cance
    Oct 7, 2021

    Testing Circulating Tumour DNA for Homologous Recombination Gene

    Recruiting
    • Circulating Tumor DNA
    • Metastatic Prostate Cancer
    • Blood sample
    • Urine sample
    • Tours, France
      University hospital
    Sep 6, 2022

    Ovarian Cancer Trial in Pittsburgh (Olaparib tablet)

    Not yet recruiting
    • Ovarian Cancer
    • Olaparib tablet
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Nov 1, 2023

    Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

    Not yet recruiting
    • Breast Cancer
    • Marseille, France
      Institut Paoli Calmettes
    Aug 9, 2023

    Metastatic Castration Resistant Prostate Cancer Trial in Worldwide (Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel)

    Active, not recruiting
    • Metastatic Castration Resistant Prostate Cancer
    • Rucaparib
    • Abiraterone acetate or Enzalutamide or Docetaxel
    • Birmingham, Alabama
    • +149 more
    Jan 19, 2023

    Solid Tumor, Adult Trial in Miami (Pembrolizumab 200 mg Q3W)

    Active, not recruiting
    • Solid Tumor, Adult
    • Pembrolizumab 200 mg Q3W
    • Miami, Florida
      Miami Cancer Institute at Baptist Health, Inc.
    Nov 18, 2022

    Advanced Cancers Trial in Boston (LY2606368)

    Active, not recruiting
    Has Results
    • Advanced Cancers
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 18, 2022

    Solid Tumor, Adult, Homologous Recombination Deficiency Trial in Washington, Hackensack, Charlotte (Niraparib, Carboplatin)

    Recruiting
    • Solid Tumor, Adult
    • Homologous Recombination Deficiency
    • Washington, District of Columbia
    • +2 more
    Aug 31, 2021

    Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (olaparib, enzalutamide, abiraterone acetate)

    Active, not recruiting
    Has Results
    • Metastatic Castration-resistant Prostate Cancer
    • Anchorage, Alaska
    • +203 more
    Jan 27, 2023

    Efficacy and Safety Trial in Zhejiang (Arsenic trioxide Tablet +Fuzuloparib Capsules)

    Recruiting
    • Efficacy and Safety
    • Arsenic trioxide Tablet +Fuzuloparib Capsules
    • Zhejiang, Hangzhou, China
      Women's Hospital School Of Medicine Zhejiang University
    Jan 23, 2022

    Ovarian Cancer, Breast Cancer, Pancreatic Cancer Trial (HS-10502)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • (no location specified)
    Feb 24, 2023

    Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)

    Not yet recruiting
    • Pancreatic Adenocarcinoma
    • Homologous Recombination Deficiency
    • (no location specified)
    Oct 18, 2023

    Breast Cancer Trial in Netherlands (Carboplatin and Paclitaxel, Doxorubicin, cyclophosphamide, Doxorubicin, cyclophosphamide,

    Active, not recruiting
    • Breast Cancer
    • Carboplatin and Paclitaxel
    • +2 more
    • Alkmaar, Netherlands
    • +13 more
    Oct 18, 2021